Hemab Therapeutics Holdings, Inc. (COAG)
Nasdaq: COAG · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2026
Who owns Hemab Therapeutics Holdings, Inc.
As filed with the SECHolders of 5% or more
9
RA Capital Management, L.P. holds 16.6% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G filed May 11, 2026 says.
Directors and officers
15
report now, of 15 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13G · filed May 11, 2026 · Common Stock, par value $0.0001 per share
Ai Den-Mab LLC
SCHEDULE 13D · filed May 11, 2026 · Common stock, par value $0.0001 per share
Novo Holdings A/S
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
Deep Track Capital, LP
SCHEDULE 13G · filed May 8, 2026 · Common stock, $0.0001 par value per share
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2026 · COMMON STOCK
Capital International Investors
SCHEDULE 13G · filed Aug 12, 2026 · Common Stock
Behzad Aghazadeh
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.001 per share
Sofinnova Crossover II SLP
SCHEDULE 13G · filed Aug 5, 2026 · Common Stock, par value $0.0001 per share
Raymond Debbane
SCHEDULE 13G · filed Aug 7, 2026 · Common Stock, $0.0001 par value per share
What COAG reports owning in othersstakes of 5% or more, and other ties
Hemab Therapeutics Holdings, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
16purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$55.5Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 21 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shah Rajeev M. | director | 0 | $0 | 0 | 6 | $52.2M |
| Ra Capital Healthcare Fund LP | director | 0 | $0 | 0 | 5 | $1.3M |
| Ra Capital Management, L.P. | director | 0 | $0 | 0 | 4 | $1.8M |
| Kolchinsky Peter | director | 0 | $0 | 0 | 1 | $200,000 |